Vertex Pharmaceuticals share price today
(NASDAQ: VRTX)

Name: Vertex Pharmaceuticals Share Price Today (NASDAQ: VRTX) - Vertex Pharmaceuticals Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Vertex Pharmaceuticals share price is $428 & ₹37,017.72 as on 23 Jan 2025, 20.31 hrs IST

$428

▲

0.11

(0.03%)

Market is closed - opens 8 PM, 23 Jan 2025

View live Vertex Pharmaceuticals share price in Dollar and Rupees. Guide to invest in Vertex Pharmaceuticals stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Vertex Pharmaceuticals, along with analyst recommendations, forecasts, and comprehensive financials.

Vertex Pharmaceuticals share price movements

Today's Low: $424.75
Today's High: $432.60
$428.00
0.76%
Downside
Day's Volatility :1.81%
Upside
1.06%
52 Weeks Low: $377.85
52 Weeks High: $519.88
$428.00
11.72%
Downside
52 Weeks Volatility :27.32%
Upside
17.67%

Vertex Pharmaceuticals Returns

Period	Vertex Pharmaceuticals Incorporated	Sector (Health Care)	S&P500
3 Months	-9.3%	-5.5%	5.0%
6 Months	-13.05%	-4.3%	9.6%
1 Year	0.1%	1.6%	25.1%
3 Years	86.35%	9.8%	38.4%

Vertex Pharmaceuticals Key Statistics

in dollars & INR

Previous Close	$428.0
Open	$427.89
Today's High	$430.82
Today's Low	$426.73
Market Capitalization	$110.2B
Today's Volume	$1.1M
52 Week High	$519.88
52 Week Low	$377.85
Revenue TTM	$10.6B
EBITDA	$4.4B
Earnings Per Share (EPS)	$-1.9
Profit Margin	-4.51%
Quarterly Earnings Growth YOY	0.01%
Return On Equity TTM	-2.98%

How to invest in Vertex Pharmaceuticals Stock (VRTX) from India?

It is very easy for Indian residents to invest directly in Vertex Pharmaceuticals from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Vertex Pharmaceuticals stock in both Indian Rupees (INR) and US Dollars (USD). Search for Vertex Pharmaceuticals or VRTX on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Vertex Pharmaceuticals or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Vertex Pharmaceuticals shares which would translate to 0.002 fractional shares of Vertex Pharmaceuticals as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Vertex Pharmaceuticals, in just a few clicks!

Returns in Vertex Pharmaceuticals for Indian investors in Rupees

Investment Value

₹1,00,000

Vertex Pharmaceuticals investment value today

Current value as on today

₹1,04,157

Returns

₹4,157

(+4.16%)

Returns from Vertex Pharmaceuticals Stock

₹103 (+0.10%)

Dollar Returns

₹4,054 (+4.05%)

Indian investors sentiment towards Vertex Pharmaceuticals

-30.88%

Period: Oct 24, 2024 to Jan 22, 2025. Change in 30 Days versus previous period

Investment in Vertex Pharmaceuticals from India has reduced in the last 30 days as on Jan 23, 2025. -30.88% less purchase transactions for Vertex Pharmaceuticals in the last 30 days versus the previous period.

-29%

Period: Oct 24, 2024 to Jan 22, 2025. Change in 30 Days versus previous period

Search volume for Vertex Pharmaceuticals on INDmoney from India has reduced in the last 30 days as on Jan 23, 2025. -29% less investors are searching Vertex Pharmaceuticals in the last 30 days versus the previous period.

Indian Mutual Funds that invest in Vertex Pharmaceuticals

Name	Shares Held	Change in Shares	% of Assets
ICICI Prudential NASDAQ 100 Index Fund Direct Growth	3353	0.00	0.66%
Motilal Oswal S&P 500 Index Fund Direct Growth	2222	-42.48	0.20%
Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth	389	0.00	0.85%

Global Institutional Holdings in Vertex Pharmaceuticals

Capital World Investors
10.41%
Vanguard Group Inc
8.99%
BlackRock Inc
8.46%
State Street Corp
4.59%
FMR Inc
4.09%
Capital Research Global Investors
3.50%

Analyst Recommendation on Vertex Pharmaceuticals

Buy

68%Buy

26%Hold

5%Sell

Based on 38 Wall street analysts offering stock ratings for Vertex Pharmaceuticals(by analysts ranked 0 to 5 stars)

Based on 38 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Vertex Pharmaceuticals

What analysts predicted

Upside of 14.44%

Target:

$489.81

Current:

$428.00

Insights on Vertex Pharmaceuticals

Price Movement
In the last 3 years, VRTX stock has moved up by 87.7%
Increasing Revenue
Vertex Pharmaceuticals Incorporated has shown positive revenue growth over the last two quarters, increasing from $2.63 billion to $2.77 billion. This reflects an average increase of 5.0% per quarter.
Increasing Net Profit
Vertex Pharmaceuticals Incorporated has seen a significant improvement in its profit over the last two quarters. The net profit increased from a loss of $3.59 billion to a profit of $1.04 billion. This represents an average increase of 443.8% per quarter, indicating a strong upward trend in the company's financial performance.
VRTX vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 40.5% return, outperforming this stock by 43.2%
VRTX vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 95.4% return, outperforming this stock by 7.7%
Price to Sales
Vertex Pharmaceuticals Incorporated has a Price-to-Sales Ratio of 10.4, meaning that for every $1 of sales, investors are willing to pay $10.4 for the company's stock. In comparison, Alnylam Pharmaceuticals, Inc. has a higher Price-to-Sales Ratio of 16.1, indicating that investors are willing to pay more for every $1 of sales from that company.

Vertex Pharmaceuticals Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$3.0B	↑ 22.46%
Net Income	$2.1B	↑ 695.83%
Net Profit Margin	68.8%	↑ 58.21%

	FY19	Y/Y Change
Revenue	$4.2B	↑ 36.59%
Net Income	$1.2B	↓ 43.88%
Net Profit Margin	28.27%	↓ 40.53%

	FY20	Y/Y Change
Revenue	$6.2B	↑ 49.07%
Net Income	$2.7B	↑ 130.43%
Net Profit Margin	43.7%	↑ 15.43%

	FY21	Y/Y Change
Revenue	$7.6B	↑ 22.06%
Net Income	$2.3B	↓ 13.63%
Net Profit Margin	30.92%	↓ 12.78%

	FY22	Y/Y Change
Revenue	$8.9B	↑ 17.91%
Net Income	$3.3B	↑ 41.84%
Net Profit Margin	37.2%	↑ 6.28%

	FY23	Y/Y Change
Revenue	$9.9B	↑ 10.51%
Net Income	$3.6B	↑ 8.96%
Net Profit Margin	36.68%	↓ 0.52%

	Q2 FY23	Q/Q Change
Revenue	$2.5B	↑ 4.99%
Net Income	$915.7M	↑ 30.85%
Net Profit Margin	36.73%	↑ 7.26%

	Q3 FY23	Q/Q Change
Revenue	$2.5B	↓ 0.39%
Net Income	$1.0B	↑ 13.06%
Net Profit Margin	41.69%	↑ 4.96%

	Q4 FY23	Q/Q Change
Revenue	$2.5B	↑ 1.38%
Net Income	$968.8M	↓ 6.42%
Net Profit Margin	38.48%	↓ 3.21%

	Q1 FY24	Q/Q Change
Revenue	$2.7B	↑ 6.73%
Net Income	$1.1B	↑ 13.5%
Net Profit Margin	40.92%	↑ 2.44%

	Q2 FY24	Q/Q Change
Revenue	$2.6B	↓ 1.95%
Net Income	$-3.6B	↓ 426.81%
Net Profit Margin	-136.4%	↓ 177.32%

	Q3 FY24	Q/Q Change
Revenue	$2.8B	↑ 5.21%
Net Income	$1.0B	↓ 129.09%
Net Profit Margin	37.71%	↑ 174.11%

	FY18	Y/Y Change
Profit	$2.6B	↑ 19.18%

	FY19	Y/Y Change
Profit	$3.6B	↑ 37.04%

	FY20	Y/Y Change
Profit	$5.5B	↑ 51.29%

	FY21	Y/Y Change
Profit	$6.7B	↑ 21.96%

	FY22	Y/Y Change
Profit	$7.9B	↑ 17.69%

	FY23	Y/Y Change
Profit	$8.6B	↑ 9.64%

	Q2 FY23	Q/Q Change
Profit	$2.2B	↑ 3.64%

	Q3 FY23	Q/Q Change
Profit	$2.2B	↓ 0.91%

	Q4 FY23	Q/Q Change
Profit	$2.1B	↓ 0.7%

	Q1 FY24	Q/Q Change
Profit	$2.3B	↑ 9.07%

	Q2 FY24	Q/Q Change
Profit	$2.3B	↓ 3.49%

	Q3 FY24	Q/Q Change
Profit	$2.4B	↑ 5.15%

	FY18	Y/Y Change
Operating Cash Flow	$1.3B	↑ 50.34%
Investing Cash Flow	$-202.2M	↓ 53.81%
Financing Cash Flow	$-71.2M	↓ 204.12%

	FY19	Y/Y Change
Operating Cash Flow	$1.6B	↑ 23.54%
Investing Cash Flow	$-1.2B	↑ 511.07%
Financing Cash Flow	$126.8M	↓ 278.0%

	FY20	Y/Y Change
Operating Cash Flow	$3.3B	↑ 107.32%
Investing Cash Flow	$99.4M	↓ 108.05%
Financing Cash Flow	$-505.3M	↓ 498.57%

	FY21	Y/Y Change
Operating Cash Flow	$2.6B	↓ 18.75%
Investing Cash Flow	$-340.9M	↓ 443.0%
Financing Cash Flow	$-1.5B	↑ 192.51%

	FY22	Y/Y Change
Operating Cash Flow	$4.1B	↑ 56.23%
Investing Cash Flow	$-321.1M	↓ 5.81%
Financing Cash Flow	$-67.7M	↓ 95.42%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$1.1B	↑ 26.06%
Investing Cash Flow	$-303.9M	↓ 83.43%
Financing Cash Flow	$17.3M	↓ 105.87%

Vertex Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Vertex Pharmaceuticals is currently in a neutral trading position according to technical analysis indicators.

Vertex Pharmaceuticals Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Vertex Pharmaceuticals Incorporated	4.86%	-13.05%	0.1%	86.35%	88.24%
Biontech Se	0.91%	36.01%	16.45%	-23.72%	246.9%
Regeneron Pharmaceuticals, Inc.	-4.82%	-36.1%	-28.29%	9.42%	100.35%
Alnylam Pharmaceuticals, Inc.	9.57%	12.05%	43.92%	95.22%	127.75%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Vertex Pharmaceuticals Incorporated	32.84	NA	1.1	0.48	-0.03	0.12	NA	60.65
Biontech Se	160.8	NA	0.04	-3.33	-0.02	-0.01	NA	79.73
Regeneron Pharmaceuticals, Inc.	17.02	17.02	1.05	44.99	0.17	0.07	NA	272.04
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.18	-15.01	-0.03	NA	0.25

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Vertex Pharmaceuticals Incorporated	Buy	$110.2B	88.24%	32.84	-4.51%
Biontech Se	Buy	$28.1B	246.9%	160.8	-15.36%
Regeneron Pharmaceuticals, Inc.	Buy	$75.6B	100.35%	17.02	33.61%
Alnylam Pharmaceuticals, Inc.	Buy	$34.2B	127.75%	NA	-15.86%

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Organization	Vertex Pharmaceuticals
Employees	5400
CEO	Dr. Jeffrey Marc Leiden M.D., Ph.D.
Industry	Health Technology

Management People of Vertex Pharmaceuticals

Name	Title
Dr. Jeffrey Marc Leiden M.D., Ph.D.	Executive Chairman
Dr. Reshma Kewalramani FASN, M.D.	CEO, President & Director
Mr. Charles F. Wagner Jr.	Executive VP & CFO
Mr. Stuart A. Arbuckle B.Sc.	Executive VP & COO
Dr. David M. Altshuler M.D., Ph.D.	Executive VP & Chief Scientific Officer
Ms. Kristen C. Ambrose CPA	Senior VP & Chief Accounting Officer
Mr. Mike Tirozzi	SVP and Chief Information & Data Officer
Ms. Susie Lisa C.F.A.	Senior Vice President of Investor Relations
Mr. Jonathan Biller J.D.	Executive VP & Chief Legal Officer
Ms. Nina Devlin	Senior VP & Chief Communications Officer

Important FAQs about investing in Vertex Pharmaceuticals (VRTX) from India :

What is Vertex Pharmaceuticals share price today?

Vertex Pharmaceuticals share price today stands at $428.00, Open: $427.89 ; Previous Close: $427.89 ; High: $432.60 ; Low: $424.75 ; 52 Week High: $519.88 ; 52 Week Low: $377.85. The stock opens at $427.89, after a previous close of $427.89. The stock reached a daily high of $432.60 and a low of $424.75, with a 52-week high of $519.88 and a 52-week low of $377.85.

Can Indians buy Vertex Pharmaceuticals shares?

Yes, Indians can invest in the Vertex Pharmaceuticals (VRTX) from India.

With INDmoney, you can buy Vertex Pharmaceuticals at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Vertex Pharmaceuticals at zero transaction cost.

How can I buy Vertex Pharmaceuticals shares from India?

It is very easy to buy Vertex Pharmaceuticals from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Vertex Pharmaceuticals be purchased?

Yes, you can buy fractional shares of Vertex Pharmaceuticals with INDmoney app.

What are the documents required to start investing in Vertex Pharmaceuticals stocks?

To start investing in Vertex Pharmaceuticals, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.